TRENDS

Transformation of ARB Market Spurred by AGs, Power Map Changing Fast as Brand-Name Drugs Falter

September 4, 2015
The market for angiotensin II receptor blockers (ARBs) has been changing rapidly over the past year as Diovan (valsartan) and Blopress (candesartan) have floundered in the face of generic debuts, while Azilva (azilsartan), launched in May 2012, has enjoyed an…

To read the full story

TRENDS

Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

By Eric Persoff

The advance of cell therapy is one of the most exciting innovations in medical treatment in recent years. These drugs offer potential curative treatments for severe or previously fatal diseases. In this article, I will explain features and challenges in…

By Izuru Ando

The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…